Tags

Type your tag names separated by a space and hit enter

High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
Bone Marrow Transplant. 2005 Nov; 36(9):813-9.BM

Abstract

Clinical impact of high-grade (HG) cytomegalovirus (CMV) antigenemia after hematopoietic stem cell transplantation has not been clarified. Therefore, in order to investigate the risk factors and outcome for HG-CMV antigenemia, we retrospectively analyzed the records of 154 Japanese adult patients who underwent allogeneic hematopoietic stem cell transplantation for the first time from 1995 to 2002 at the University of Tokyo Hospital. Among 107 patients who developed positive CMV antigenemia at any level, 74 received risk-adapted preemptive therapy with ganciclovir (GCV), and 17 of these developed HG-antigenemia defined as > or = 50 positive cells per two slides. The use of systemic corticosteroids at > or = 0.5 mg/kg/day at the initiation of GCV was identified as an independent significant risk factor for HG-antigenemia. Seven of the 17 HG-antigenemia patients developed CMV disease, with a cumulative incidence of 49.5%, which was significantly higher than that in the low-grade antigenemia patients (4%, P<0.001). However, overall survival was almost equivalent in the two groups. In conclusion, the development of HG-antigenemia appeared to depend on the profound immune suppression of the recipient. Although CMV disease frequently developed in HG-antigenemia patients, antiviral therapy could prevent a fatal outcome.

Authors+Show Affiliations

Department of Cell Therapy & Transplantation Medicine, University of Tokyo, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16151428

Citation

Asano-Mori, Y, et al. "High-grade Cytomegalovirus Antigenemia After Hematopoietic Stem Cell Transplantation." Bone Marrow Transplantation, vol. 36, no. 9, 2005, pp. 813-9.
Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(9):813-9.
Asano-Mori, Y., Oshima, K., Sakata-Yanagimoto, M., Nakagawa, M., Kandabashi, K., Izutsu, K., Hangaishi, A., Motokura, T., Chiba, S., Kurokawa, M., Hirai, H., & Kanda, Y. (2005). High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 36(9), 813-9.
Asano-Mori Y, et al. High-grade Cytomegalovirus Antigenemia After Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. 2005;36(9):813-9. PubMed PMID: 16151428.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. AU - Asano-Mori,Y, AU - Oshima,K, AU - Sakata-Yanagimoto,M, AU - Nakagawa,M, AU - Kandabashi,K, AU - Izutsu,K, AU - Hangaishi,A, AU - Motokura,T, AU - Chiba,S, AU - Kurokawa,M, AU - Hirai,H, AU - Kanda,Y, PY - 2005/9/10/pubmed PY - 2006/1/13/medline PY - 2005/9/10/entrez SP - 813 EP - 9 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 36 IS - 9 N2 - Clinical impact of high-grade (HG) cytomegalovirus (CMV) antigenemia after hematopoietic stem cell transplantation has not been clarified. Therefore, in order to investigate the risk factors and outcome for HG-CMV antigenemia, we retrospectively analyzed the records of 154 Japanese adult patients who underwent allogeneic hematopoietic stem cell transplantation for the first time from 1995 to 2002 at the University of Tokyo Hospital. Among 107 patients who developed positive CMV antigenemia at any level, 74 received risk-adapted preemptive therapy with ganciclovir (GCV), and 17 of these developed HG-antigenemia defined as > or = 50 positive cells per two slides. The use of systemic corticosteroids at > or = 0.5 mg/kg/day at the initiation of GCV was identified as an independent significant risk factor for HG-antigenemia. Seven of the 17 HG-antigenemia patients developed CMV disease, with a cumulative incidence of 49.5%, which was significantly higher than that in the low-grade antigenemia patients (4%, P<0.001). However, overall survival was almost equivalent in the two groups. In conclusion, the development of HG-antigenemia appeared to depend on the profound immune suppression of the recipient. Although CMV disease frequently developed in HG-antigenemia patients, antiviral therapy could prevent a fatal outcome. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/16151428/High_grade_cytomegalovirus_antigenemia_after_hematopoietic_stem_cell_transplantation_ L2 - https://doi.org/10.1038/sj.bmt.1705134 DB - PRIME DP - Unbound Medicine ER -